Saudi-Arabia - englanti - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

upjohn eesv, netherlands - tadalafil - film-coated tablet - 5 mg,

Saudi-Arabia - englanti - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

upjohn eesv, netherlands - sildenafil - tablet - 50 mg

Saudi-Arabia - englanti - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

upjohn eesv, netherlands - sildenafil - tablet - 50 mg

Australia - englanti - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - neomycin as the sulfate - oral powder, pre-mix - neomycin as the sulfate antibiotic active 1000.0 g/kg - nutrition & metabolism - cattle | pigs | poultry | beef | boar | bos indicus | bos taurus | bovine | breeders | broiler | buffalo | bull | bullock | calf - bacterial enteritis | escherichia coli (e. coli) | proteus spp. | pseudomonas spp. | salmonella | including b-lactamase producin | post-weaning bacterial enterit | salmonellosis

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - alprazolam 0.25mg (exclusive of 1.5% excess.);  ;   - tablet - 0.25 mg - active: alprazolam 0.25mg (exclusive of 1.5% excess.)     excipient: colloidal silicon dioxide [docusate sodium (85% ) with sodium benzoate [15%] lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - 1. anxiety states (anxiety neuroses). symptoms which occur in such patients include anxiety, tension, fear, insomnia, apprehension, restlessness, concentration difficulties, irritability and/or autonomic hyperactivity resulting in a variety of somatic complaints. 2. mixed anxiety-depression. symptoms of both anxiety and depression occur concurrently in such patients. 3. neurotic or reactive depression. such patients primarily exhibit a depressed mood or a pervasive loss of interest or pleasure. other characteristics include anxiety, appetite disturbances, changes in weight, cognitive disturbances, decreased energy, feeling of worthlessness or guilt, insomnia, somatic complaints, or thoughts of death or suicide. 4. anxiety states, mixed anxiety-depression, or neurotic depression associated with other diseases such as the chronic phase of alcohol withdrawal and functional or organic disease, particularly certain gastrointestinal, cardiovascular, or dermatological disorders.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - alprazolam 0.5mg (exclusive of 1.5% excess.);  ;   - tablet - 0.5 mg - active: alprazolam 0.5mg (exclusive of 1.5% excess.)     excipient: colloidal silicon dioxide docusate sodium erythrosine lactose monohydrate magnesium stearate maize starch microcrystalline cellulose sodium benzoate - 1. anxiety states (anxiety neuroses). symptoms which occur in such patients include anxiety, tension, fear, insomnia, apprehension, restlessness, concentration difficulties, irritability and/or autonomic hyperactivity resulting in a variety of somatic complaints. 2. mixed anxiety-depression. symptoms of both anxiety and depression occur concurrently in such patients. 3. neurotic or reactive depression. such patients primarily exhibit a depressed mood or a pervasive loss of interest or pleasure. other characteristics include anxiety, appetite disturbances, changes in weight, cognitive disturbances, decreased energy, feeling of worthlessness or guilt, insomnia, somatic complaints, or thoughts of death or suicide. 4. anxiety states, mixed anxiety-depression, or neurotic depression associated with other diseases such as the chronic phase of alcohol withdrawal and functional or organic disease, particularly certain gastrointestinal, cardiovascular, or dermatological disorders.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - alprazolam 1mg (exclusive of 1.5% excess.);  ;   - tablet - 1 mg - active: alprazolam 1mg (exclusive of 1.5% excess.)     excipient: colloidal silicon dioxide erythrosine indigo carmine docusate sodium (85%) with sodium benzoate (15%) lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - 1. anxiety states (anxiety neuroses). symptoms which occur in such patients include anxiety, tension, fear, insomnia, apprehension, restlessness, concentration difficulties, irritability and/or autonomic hyperactivity resulting in a variety of somatic complaints. 2. mixed anxiety-depression. symptoms of both anxiety and depression occur concurrently in such patients. 3. neurotic or reactive depression. such patients primarily exhibit a depressed mood or a pervasive loss of interest or pleasure. other characteristics include anxiety, appetite disturbances, changes in weight, cognitive disturbances, decreased energy, feeling of worthlessness or guilt, insomnia, somatic complaints, or thoughts of death or suicide. 4. anxiety states, mixed anxiety-depression, or neurotic depression associated with other diseases such as the chronic phase of alcohol withdrawal and functional or organic disease, particularly certain gastrointestinal, cardiovascular, or dermatological disorders.

Malta - englanti - Malta Medicines Authority

viatris hellas ltd 253-255, mesogion avenue, 154 51 neo psychiko, athens,, greece - atorvastatin - film-coated tablet - atorvastatin 10 mg - lipid modifying agents

Malta - englanti - Malta Medicines Authority

viatris hellas ltd 253-255, mesogion avenue, 154 51 neo psychiko, athens,, greece - atorvastatin - film-coated tablet - atorvastatin 20 mg - lipid modifying agents

Malta - englanti - Malta Medicines Authority

viatris hellas ltd 253-255, mesogion avenue, 154 51 neo psychiko, athens,, greece - atorvastatin - film-coated tablet - atorvastatin 40 mg - lipid modifying agents